Background and Aims: Influenza A virus of Orthomyxoviridae family is able to create pandemic influenza. Vaccination is the most effective way to prevent influenza virus infection. Matrix protein 2 (M2) is a homotetramer ion channel with 97 amino acids length and highly conserved among influenza viruses and is considered for development of a universal influenza vaccine.
Introduction nfluenza A viruses are capable of infecting human and causing pandemic flu (1) . With regard to the mortality and complications for the elderly and vulnerable people, influenza is potentially a dangerous viral infection (2, 3) . Statistical analysis in The United States of America indicate that Influenza A virus causes 20000 to 40000 death and over 100000
hospitalization every year (4) . Influenza A virus genome consists of 8 single strand segments of RNA with negative polarity producing structural and nonstructural proteins of the virus. Structural proteins such as haemagglutinin (HA), neuraminidase (NA) and M2 are located in the virus envelope (1) . M2 protein is a membrane-bound homotetramer with pH-inducible proton transfer activity (5) . It enables hydrogen ions entry from the endosome, causing dissociation of the viral matrix protein M1 from the ribonucleoprotein RNP (5, 6) . M2 is a small viral protein, composed of 97 amino acids including a portion of the 54 cytoplasmic Over Expression of Influenza Virus M2 Protein … amino acids, 19 transmembrane amino acids and 23 ectodomain amino acids(M2e) (7) . In contrast to HA, M2 is highly conserved among all influenza A subtypes (8) . It increases immune response and protects against lethal challenge with influenza A virus, therefore it is considered as a suitable target for development of vaccine with broad-spectrum protection (5) (6) (7) (8) (9) . Recent studies have shown that antibodies against the influenza A virus M2e has reduced viral load in the challenged mouse lungs (10) . In addition, several studies have demonstrated efficiency of different tandem repeats of M2e sequence (11) . Eliasson et al demonstrated that immunization with three repeats of M2e and CTA1-DD adjuvant induced effective mucosal immunity and T-cell stimulation in mice against lethal challenge with influenza virus (12) . Different strategies have been used to design M2 protein based vaccines. Since M2 does not induce enough immune responses to protect against infection, therefore M2 vaccine has been conjugated with different carriers like Neisseria meningitidis outer membrane protein complex (OMPC), hepatitis B virus core antigen (HBVc), or keyhole limpet hemocyanin (KLH). Reports have demonstrated that these improvements can induce antigen-specific antibody responses and protect mice against influenza virus lethal challenge (13) . We previously constructed recombinant pQE30-M2 plasmid and expressed the M2 protein in E.coli host strain M15 (14) . In this report, we describe the over expression of M2 protein in E.coli host strain BL21 using pET28a vector and compared protein production efficacy in these different hosts. This is the first step of our project focusing on production of an efficient universal subunit vaccine against different influenza viruses.
Methods

M2 gene amplification and subcloning into pET28a
Full length of the M2 gene has previously been amplified by PCR using influenza Virus mRNA, cloned into pGEMTeasy vector and sequenced (15) . A specific primer set previously used for amplification of M2 DNA was modified to incorporate desired restriction enzyme sites (BamHI and Hind III) in the 5' ends of the gene. The PCR product was cleaned up and annealed by ligation to the pET28a expression vector using T4 DNA ligase and transformed into competent E.coli Top10F' cells. Colony PCR and restriction enzyme analysis were conducted to monitor transformants.
Recombinant pET28a-M2 plasmid was purified using Mini preparation kit (iNtRON Biotechnology, Inc.) and finally confirmed by sequencing.
Expression of M2 protein in E. coli
Recombinant plasmid pET28a-M2 was transferred into E. coli BL21 strain and cultured in LB agar plate containing 50μg/ml kanamycin and 50μg/ml tetracycline. Then the selected colonies were grown in LB broth at 37°C with shaking at 185 rpm. Expression of influenza M2 protein was induced by addition of 0.5mM of isopropylthiogalactoside (IPTG) at OD600 = 0.6. Samples were collected by centrifugation at 9000 g for 3 min at 4°C before induction at different time point after. Protein expression analysis M2 expression was determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) using the method of Laemmli. Bacterial pellet was mixed with 2x sample buffer (100mM Tris HCl pH 8, 20% glycerol, 4% SDS, 2% 2-ME 0.2% bromo phenol blue), and boiled for 5 minutes. Following electrophoresis, the gel was stained with coomassie brilliant blue R-250.
Western blot analysis/Immunoblotting
Recombinant protein was electrophoresed on 12% polyacrylamide gel and then transferred to nitrocellulose membrane (Sartorius, Germany). The expected M2 protein was detected using monoclonal antibody (Antibody 5416, Abcam, Cambridge, MA) as primary antibody and Peroxidase-conjugated goat antimouse immunoglobulin (Dako) as secondary antibody.
Diamino benzoic acid (DAB, Amersham Bioscience, Piscataway, NJ, USA) was used as the chromogenic substrates in final step.
A r c h i v e o f S I D www.SID.ir
One-step Protein purification of His-tagged M2
Recombinant proteins expressed in E.coli, usually accumulated in insoluble aggregated, called inclusion bodies. In this study inclusion bodies solubilized using buffers containing 8M urea. Cell pellet from an E.coli BL21 expression culture, were disrupted under denaturing condition and sonicated (10 × 15s bursts with a 15 s cooling period between each burst). For better dissolution, the inclusion bodies were stirred on ice for 60min, and then centrifuged at 10000g for 30min. 
Results
Insilico analysis
The full length of human influenza M2 gene (A/H1N1) was cloned in plasmid pET28a in frame with histidine residue at both C-and Nterminal. According to the Expasy online database surveys, the M2 protein produced in E.coli BL21 contains 144 amino acids with about 16.12kD molecular weight. It encodes M2 protein (97aa) plus 46 extra amino acids at both sides. The related isoelectric pH was around 6.58. This information was used in protein purification process. M2 gene sequence with 6xHIS tagged sequence at both side Recombinant pET28a-M2 was transferred into E.coli host strain BL21(DE3) and samples were collected at 2,3,4 and 20 hours after IPTG induction and disrupted by lysis buffer. Protein bands were visualized on 12% polyacrylamide gel ( Fig. 1) and confirmed by Western-blotting using monoclonal anti-M2 antibody (Fig. 2) . SDS-PAGE analysis demonstrated an approximately 17KD band as expected. Protein 
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expression was detectable after one hour and reached to highest amount after two hours. Overnight incubation at 37°C decreased the protein expression. The yield of M2 protein production was analyzed using Quantity One software. The results showed that the recombinant M2 protein was about 21% of the total BL21 proteins. We previously constructed recombinant pQE30-M2 plasmid and expressed the M2 protein in E.coli host strain M15 (15) . M2 protein production in BL21 and M15 cells was compared using Quantity One software (Fig.  3) . The results showed that the yield of M2 protein in BL21 cells was at least 3 times more than its production in M15.
Purification of M2 protein
The recombinant protein was purified with Ni-TED column chromatography and electrophoresed on 12% SDS-PAGE (Fig. 4) . The results of SDS-PAGE showed that the purification of M2 protein using this system was very specific.
Discussion
A comprehensive vaccine that can induce protection against different influenza viruses has become a research emphasis. A limitation of current vaccines is that the major vaccine targets, the antigenic regions of HA and NA, are highly susceptible to continuous mutation 
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in circulating epidemic virus strains. There are various projects in the context of different universal influenza vaccines at the base of conserved sequences of viral proteins (1) . Developing universal influenza vaccines that have protection against different types of influenza virus and even pandemic strains needs to identify conserved areas in influenza virus proteins. In influenza A viruses, the M2 protein is highly conserved among and within different subtypes and is therefore an attractive target antigen for vaccines that could provide cross-strain protection. Therefore, recombinant vaccine technologies based on M2 protein has been investigated widely (1) . External domain of highly conserved M2 protein has been proposed to develop universal influenza vaccines. Recent studies with induced protective immune responses and broad spectrum protection has created hopes on further development of safe universal influenza vaccines against seasonal and pandemic influenza in the near future )14-20(. In the present study, full-length M2 gene of the seasonal human influenza virus A/NewCaledonia/20/99 (H1N1) was subcloned into pET28a under the control of T7 promoter. T7 RNA polymerase activity is around five times more than E.coli RNA polymerase (22) . So it has been expected overexpression of the genes under control of T7 promoter. E.coli strain BL21 (DE3) is highly used to produce cloned proteins in plasmid vectors containing T7 promoter. In comparison to M2 expression in M15 cells using pQE30 expression vector in our previous study (14) , we showed that the M2 expression using this system is much more valuable and cost effective for M2 production in prokaryotic system than the previous one. The expressed M2 protein showed to have an apparent molecular weight around 17kD as estimated by Expasy online database and reacted specifically with commercial anti-M2 monoclonal antibody in Western blot analysis. As the recombinant M2 protein prepared here has histidine residue at both terminals, it was successfully purified in one-step purification procedure.
Conclusion
In summary, our study showed successful use of pET28a plasmid for cloning and expression of influenza virus M2 protein as a fusion with 6-His tag in Escherichia coli BL21strain. In order to design an effective and protective vaccination regimen, we are going to evaluate immunogenicity of the purified M2 protein with different adjuvant and/or M2-DNA vaccine in animal model.
